STOCK TITAN
  1. Home
  2. PRCWF

Sofgen Pharma S.A WTS (PRCWF) Stock Price, News & Analysis

PRCWF OTC
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
1 7 sessions, August 26, 2025 to May 21, 2026
Largest daily move
+100% close of April 10, 2026
1-month change
+0% closing prices, April 17, 2026 to May 21, 2026

Company Description

PRCWF gained 0.0% in the month to May 21, 2026. The last closing price was $0.0002.

For FY2024, Sofgen Pharma S.A WTS reported revenue of $373.8M with net income of -$68.3M and diluted earnings per share of -$0.68. The company operates at a net profit margin of -18.3%.

This page collects what Stock Titan holds for PRCWF, including price data, SEC filings, financial highlights, and short interest trends.

Stock Performance

Chart
$0.0002
No recent trading
Last close: May 21, 2026
+0%
1 month to May 21, 2026
-
Market Cap
-
Shares outstanding

Sofgen Pharma S.A WTS (PRCWF) closed at $0.0002 on May 21, 2026. In the month to May 21, 2026, the price gained 0.0%.

See what a $1,000 investment in PRCWF would be worth today

Average down calculator for PRCWF

PRCWF Metrics & Rankings

Revenue
$373.8M
#2,651
Piotroski F-Score
3/8 Partial
#5,119
May 2026
+0.0%
—

Price returns through May 21, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

View All

No recent news available for PRCWF.

SEC Filings

View All

[3] Chief Commercial Officer at Sofgen Pharma (PRCWF) named reporting insider in Form 3

[3] No insider trades in Sofgen Pharma (PRCWF) director Alberto Eguiguren Form 3

[3] Sofgen Pharma (PRCWF) director Carlos Garcia Iragorri files Form 3 with no reported trades

[3] Sofgen Pharma (PRCWF) director Bernal Jaramillo submits initial Form 3

[3] Large indirect Sofgen Pharma (PRCWF) stake and warrant disclosed in Form 3

[3] Sofgen Pharma (PROCF) director files Form 3 initial ownership

Sofgen Pharma S.A WTS has filed 6 recent SEC filings, including 6 Form 3. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all PRCWF SEC filings →

Financial Highlights

View Full Financials

Sofgen Pharma S.A WTS generated $373.8M in revenue in FY2024, retaining a 51.2% gross margin, operating income reached -$54.0M (-14.4% operating margin), and net income was -$68.3M, reflecting a -18.3% net profit margin. Diluted earnings per share stood at -$0.68. The company generated $88.4M in operating cash flow. The current ratio was 0.52, measuring current assets divided by current liabilities.

$373.8M
Revenue (FY2024)
-$68.3M
Net Income (FY2024)
-$0.68
Diluted EPS (FY2024)
$88.4M
Operating Cash Flow
-18.3%
Net Profit Margin
-14.4%
Oper. Profit Margin

Upcoming Events

No upcoming events scheduled for PRCWF.

Short Interest History

Last 12 Months

Short interest in Sofgen Pharma S.A WTS (PRCWF) currently stands at 800 shares.

Days to Cover History

Last 12 Months

Days to cover for Sofgen Pharma S.A WTS (PRCWF) currently stands at 1000.0 days. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.0 to 1000.0 days.

Frequently Asked Questions

Sofgen Pharma S.A WTS (PRCWF) has no recent trading. Its last close was $0.0002 on May 21, 2026.

The FY2024 revenue of Sofgen Pharma S.A WTS (PRCWF) is $373.8M, from its most recent completed fiscal year.

The FY2024 net income of Sofgen Pharma S.A WTS (PRCWF) is -$68.3M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Sofgen Pharma S.A WTS (PRCWF) is -$0.68 for FY2024, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Sofgen Pharma S.A WTS (PRCWF) is $88.4M for FY2024, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Sofgen Pharma S.A WTS (PRCWF) is -18.3% for FY2024, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Sofgen Pharma S.A WTS (PRCWF) is -14.4% for FY2024, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Sofgen Pharma S.A WTS (PRCWF) is 51.2% for FY2024, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Sofgen Pharma S.A WTS (PRCWF), current assets divided by current liabilities, was 0.52 at the end of FY2024, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Sofgen Pharma S.A WTS (PRCWF) is $191.5M for FY2024, its most recent completed fiscal year.

The operating income of Sofgen Pharma S.A WTS (PRCWF) is -$54.0M for FY2024, its most recent completed fiscal year. Learn about operating income.